Say you own 75% of your company. Your co-founder holds about 20%, with the rest reserved for the option pool. You’re the only one on the board, and you’re about to raise a Series A. That means giving a board seat to your lead investor.
One founder director, one investor director, no board majority.
Say you also want to sell some shares in a secondary down the road. If you're holding standard common stock when you do, you could face a federal tax bill $85,000 higher than it needs to be on a $500,000 sale.
These are two separate problems with two separate fixes. Both require amending your charter. And both need to happen now, while you still have the unilateral authority to do it, not after a priced round when you need board approval, investor consent, and a different negotiation entirely.
Problem one: losing board control
This is becoming more common as founding teams get smaller.
Carta’s 2025 Solo Founders Report found that 35% of U.S. startups incorporated in 2024 had a single founder, up from 17% in 2017. AI is doing a lot of the work that used to require a co-founder. A single technical founder can now build a working product and reach Series A milestones with a two- or three-person team, or alone.
You don’t need to be a solo founder to have this exposure. In the scenario above, there’s a co-founder. The equity split is just unequal enough that only the majority founder took a board seat. Plenty of two-person teams have the same arrangement without thinking through what it means once an investor director joins.
The solution is a dual-vote board seat. Two ways to maintain board control. First, add another director before the round: a co-founder, an advisor, someone aligned with the founders. Second (and this is what most founders I work with end up choosing) amend the charter so the founder’s board seat carries two votes.
Both are legal and defensible. Dual-vote is more popular because it doesn’t require finding and onboarding a new director, and it scales as your board grows through subsequent rounds.
One thing to get right: timing. A dual-vote structure installed before the term sheet is signed reads as reasonable governance. The same move attempted mid-negotiation, after a lead investor has already signaled terms, looks adversarial.
Problem two: the secondary-sale tax trap
This one catches founders off-guard because the cost is measured in dollars.
A founder holding standard common stock who sells shares in a secondary, whether directly to a new investor or through a company-facilitated tender offer, can walk into a serious tax problem. If you sell common stock above its current 409A fair market value, the IRS may treat the difference between the sale price and the FMV as compensatory income. That gain above FMV gets taxed at ordinary income rates, not capital gains rates. It may also trigger employment taxes.
Say you’re selling $500,000 in shares at your Series A. If the gain is treated as ordinary income, you’re looking at up to 37% federal, plus the 3.8% net investment income tax, for a total of at least 40.8%, and potentially more once employment taxes are factored in. On $500,000, that’s at least $204,000.
If the same gain qualifies as a long-term capital gain (you held the shares for more than a year), the rate drops to 20% plus the 3.8% NIIT: 23.8% total. On $500,000, about $119,000.
That's an $85,000 difference on a single sale.
Now factor in QSBS. Under Section 1202 of the Internal Revenue Code, founders of qualifying C corporations can exclude up to 100% of capital gains on the sale of qualified small business stock. The core requirements: the company is a domestic C corp, its gross assets are below the statutory threshold when the stock is issued, the stock is acquired at original issuance, and the founder holds it for the required period.
The One Big Beautiful Bill Act, signed July 4, 2025, changed the rules for stock issued on or after that date. The per-issuer exclusion cap went from $10 million to $15 million. The gross asset threshold went from $50 million to $75 million. And there’s a new tiered exclusion: 50% at three years, 75% at four, 100% at five. Stock issued before July 5, 2025 keeps the old rules: $10 million cap, $50 million asset threshold, five-year hold for the full exclusion, no partial exclusion at shorter holding periods.
If your shares qualify and the gain is treated as a capital gain, the federal tax on that $500,000 sale could be zero.
The catch: QSBS only applies to capital gains. If the IRS treats your secondary-sale proceeds as compensatory income, the exclusion is gone.
The solution is founders preferred stock. We use a separate class of stock, sometimes called Series FF, created through a charter amendment. It converts to the preferred stock issued in your next financing round when the shares are sold. Because the founder is selling preferred stock rather than common at a premium to FMV, the transaction is less likely to trigger the compensatory income argument. The proceeds get capital gains treatment, and the QSBS exclusion can apply.
Founders preferred typically covers 10% to 25% of a founder's shares, not the full stake. The shares must be fully vested with no repurchase restrictions. The IRS hasn't issued formal guidance blessing this structure, though it's widely used and tax practitioners generally view it as defensible. Any founder considering this should work with a tax advisor on the specifics.
Not all versions of founders preferred are equal. Some carry enhanced liquidation preferences or other economic rights that change the payout waterfall. Those create friction with incoming investors. The version I'm describing, the tax-treatment version, doesn't touch investor economics. It exists solely to improve the founder's tax position on a secondary sale. That's why it's the most widely accepted type and the one least likely to create problems in a Series A negotiation.
Both fixes require amending your charter
You file a restated certificate of incorporation with the Delaware Division of Corporations (or your state's equivalent, though most VC-backed startups are Delaware corps). Your board approves it, your stockholders with sufficient voting power approve it, and you submit the filing. At the pre-Series A stage, you and your co-founder likely hold enough shares to constitute the required vote. The stockholder approval is often a written consent you can execute the same day.
The state filing fee runs a few hundred dollars. We turn this around in a day or two, and the whole process is far simpler before your Series A than after.
The window shuts the moment your investor's money hits the account and the new governance structure takes effect. Before a priced round, you and your co-founder can approve a restated certificate and file it in days. After, you need board approval (which now includes your investor director), possibly investor consent under protective provisions, and you're negotiating from a weaker position.
If you're six months from a Series A, or six weeks, have this conversation with your lawyer now. Not during diligence, when you're already buried. Now, while the leverage is yours.